文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

作者信息

Gormley Nicole J, Pazdur Richard

机构信息

From the Food and Drug Administration, Silver Spring, MD.

出版信息

N Engl J Med. 2018 Nov 8;379(19):1791-1795. doi: 10.1056/NEJMp1803602.

DOI:10.1056/NEJMp1803602
PMID:30403935
Abstract
摘要

相似文献

[1]
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.

N Engl J Med. 2018-11-8

[2]
[Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].

Internist (Berl). 2019-6

[3]
Elotuzumab in multiple myeloma.

Lancet Oncol. 2018-12

[4]
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med. 2018-11-8

[5]
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.

Melanoma Res. 2015-4

[6]
Isatuximab: First Approval.

Drugs. 2020-6

[7]
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Oncologist. 2017-9-13

[8]
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.

Blood Cancer J. 2021-10-20

[9]
Lenalidomide in multiple myeloma.

Expert Rev Anticancer Ther. 2015-5

[10]
Second elotuzumab triplet efficacious in MM.

Nat Rev Clin Oncol. 2019-2

引用本文的文献

[1]
Targeted immunotherapy: harnessing the immune system to battle multiple myeloma.

Cell Death Discov. 2024-1-27

[2]
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.

J Clin Oncol. 2023-5-20

[3]
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.

Blood Adv. 2023-4-11

[4]
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma.

Hematology Am Soc Hematol Educ Program. 2022-12-9

[5]
Bone marrow niche in multiple myeloma and its precursor states.

Hemasphere. 2019-6-30

[6]
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.

Semin Oncol. 2022-2

[7]
Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond.

Cancers (Basel). 2021-10-9

[8]
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.

Cancers (Basel). 2021-8-26

[9]
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Blood Cancer Discov. 2021-7

[10]
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.

Oncologist. 2021-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索